The CFB inhibitor Iptacopan, developed by Novartis, has already received approval from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH)57,58 and has been investigated in clinical trials for C3 glomerulopathy59 and IgA nephropathy.60 We hypothesize that Iptacopan could also serve as a potential therapeutic option for SLE. Here, CFB is linked to IgA glomerulonephritis.